Research Article
Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation
Table 3
Patient and tumor characteristics effect on 5-year overall and recurrence free survival.
| | 5 Year Overall Survival | 5 Year Recurrence Free Survival | HR (CI) | P value | HR (CI) | P value |
| Age | 0.99 (0.96-1.03) | 0.71 | 0.96 (0.91-1.02) | 0.14 |
| Gender | HR of Female to Male | 1.19 (0.58-2.43) | 0.64 | 0.30 (0.04-2.35) | 0.25 |
| Race | HR of other races to White, non-Hispanics | 1.36 (0.68-2.73) | 0.38 | 3.56 (1.15-11.05) | 0.03 |
| Etiology | HR HCV to non HCV | 1.21 (0.58-2.54) | 0.61 | 0.69 (0.21-2.28) | 0.54 |
| MELD | | 1.01 (0.97-1.05) | 0.73 | 1.00 (0.93-1.07) | 0.99 |
| AFP | HR of >300 to ≤300 | 3.16 (1.40-7.15) | 0.006 | 8.78 (2.64-29.24) | 0.0004 |
| Tumor on explant | 1.38 (0.58-3.29) | 0.47 | 2.72 (0.35-21.07) | 0.34 |
| Histological Stage | T1 | 1.55 (0.44-5.43) | 0.50 | 9236 | 0.93 | T2 | 2.00 (0.59-6.61) | 0.27 | 28440 | 0.93 | T3 | 2.08 (0.35-12.44) | 0.42 | 82832 | 0.92 |
| Histological class | Well differentiated | 0.67 (0.25-1.76) | 0.41 | 0 | 0.97 | Moderate or poorly differentiated | 1.00 (0.47-2.14) | 0.99 | 5.02 (0.64-39.18) | 0.12 |
| Microvascular invasion | 2.36 (1.20-4.64) | 0.01 | 4.05 (1.28-12.75) | 0.02 |
| NLR | HR of ≥5 to <5 | 1.75 (0.91-3.35) | 0.09 | 1.64 (0.50-5.46) | 0.42 |
| dNLR | HR of ≥3 to <3 | 1.76 (0.86-3.61) | 0.12 | 1.87 (0.51-6.92) | 0.35 |
| LMR | HR of ≥3.45 to <3.45 | 0.62 (0.32-1.22) | 0.17 | 0.29 (0.06-1.34) | 0.11 |
| PLR | HR of ≥150 to <150 | 3.18 (1.66-6.11) | 0.001 | 7.95 (2.52-25.09) | 0.0004 |
|
|
AFP, alpha fetoprotein; dNLR, derived neutrophil lymphocyte ratio; HCV, hepatitis C virus; HR, hazard ratio; LMR, lymphocyte monocyte ratio; MELD, Model for End Stage Liver Disease; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio.
|